Moderna Signs Five-Year Strategic Agreement with Mexico for mRNA Manufacturing and Vaccine Supply
Key Insights
Moderna has signed a five-year strategic agreement with the Mexican Government to enhance Mexico's health sovereignty and mRNA manufacturing resilience through technology transfer and vaccine supply.
The agreement includes technology transfer to Laboratorios Liomont (search) for domestic manufacturing of Moderna's COVID-19 (search) vaccine mRNA-1273 and supply of the company's respiratory vaccine portfolio.
This collaboration supports Mexico's "Plan Mexico" initiative to build local mRNA ecosystem and strengthen pandemic preparedness while providing Moderna with geographic diversification opportunities.
Moderna, Inc. has announced a significant five-year strategic agreement with the Mexican Government, marking a major expansion of mRNA manufacturing capabilities in Latin America. The Memorandum of Understanding (MoU) involves partnerships with Laboratorios de Biológicos y Reactivos de Mexico (BIRMEX (search)) and Laboratorios Liomont (search) to enhance Mexico's health sovereignty and mRNA manufacturing resilience.
Technology Transfer and Manufacturing Partnership
The strategic agreement centers on technology transfer to Laboratorios Liomont (search), a Mexican pharmaceutical company with state-of-the-art manufacturing facilities, to produce mRNA-1273, Moderna's COVID-19 (search) vaccine. This initiative will establish a reliable in-country supply of respiratory vaccines and represents a significant step toward Mexico's pharmaceutical independence.
"We are proud to support Mexico in its mission to strengthen national health security," said Stéphane Bancel, Chief Executive Officer of Moderna. "Through this agreement, we will be able to provide the Mexican people with access to our respiratory vaccines and critical pandemic response capacity."
Supporting Plan Mexico Initiative
The collaboration directly supports "Plan Mexico," the Mexican government's strategic initiative to increase investment and build local production capacity for mRNA technologies. Beyond manufacturing, Moderna and the Mexican Government will collaborate on local clinical research and development programs based on Mexico's health priorities and work to strengthen the country's pandemic preparedness framework.
The agreement includes supply of Moderna's entire respiratory vaccine portfolio, providing Mexico with comprehensive access to the company's vaccine technologies. This partnership reflects what Bancel described as "the growing demand for these vaccines in Mexico" and represents an opportunity for Moderna to support public health needs while driving sales growth through geographic diversification.
Recent Regulatory Milestones
The strategic agreement builds on recent regulatory successes in Mexico. The Federal Commission for the Protection against Sanitary Risk (COFEPRIS (search)) recently approved Moderna's 2025-2026 COVID-19 (search) vaccine for individuals aged 6 months and older. Additionally, the Government of Mexico has adjudicated a purchase agreement for the supply of up to 10 million doses of Moderna's 2025-2026 COVID-19 vaccine to Logística y Transporte para la Industria de la Salud, S.A.P.I. de C.V. (Medistik (search)).
Broader mRNA Platform Impact
This agreement represents another expansion of Moderna's global mRNA platform, which the company describes as enabling "the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more." The technology transfer to Mexico demonstrates the scalability of mRNA manufacturing technologies and their potential for addressing regional health security needs.
The five-year timeline of the agreement provides a substantial foundation for building Mexico's mRNA manufacturing capabilities while ensuring sustained access to Moderna's respiratory vaccine portfolio for the Mexican population.